Гомеостаз В-лимфоцитов и направления анти-В-клеточной терапии при ревматоидном артрите

1. <div><p>Насонов Е.Л., Каратеев Д.Е., Балабанова Р.М. Ревматоидный артрит. В кн.: Ревматология: Национальное руководство. Под ред. Е.Л. Насонова, В.А. Насоновой. М.:ГЭОТАР-Медиа, 2008; 290-331.</p><p>Klareskog L., Catrina A.I., Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.</p><p>Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010;376:1094-108.</p><p>Carson D.A., Chen P.P., Kipps T.J. New roles for rheumatoid factor. J Clin Invest 1991;87:379-83.</p><p>Edwards J.C., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001;40:205-11.</p><p>Kim H.J., Berek C. B cells in rheumatoid arthritis. Arthr Res 2000;2:126-31.</p><p>Metlay J.P., Pure E., Steinman R.M. Control of the immune response at the level of antigen-presenting cells: a comparison of the function of dendritic cells and B lymphocytes. Adv Immunol 1989;47:45-116.</p><p>Takemura S., Klimiuk P.A., Braun A. et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8.</p><p>Dörner T., Lipsky P.E. B-cell targeting: a novel approach to immune intervention today and tomorrow. Expert Opin Biol Ther 2007;7:1287-99.</p><p>Dö rner T., Jacobi A.M., Lipsky P.E. B cells in autoimmunity. Arthr Res Ther 2009;11:247.</p><p>Sims G.P., Ettinger R., Shirota Y. et al. Identification and characterization of circulating human transitional B cells. Blood 2005;105:4390-8.</p><p>Anolik J.H., Looney R.J., Lund F.E. et al. Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets. Immunol Res 2009;45:144-58.</p><p>Sanz I., Wei C., Lee F.E., Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 2008;20:67-82.</p><p>Jacobi A.M., Reiter K., Mackay M. et al. Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: delineation by expression of CD27, IgD, and CD95. Arthr Rheum 2008;58:1762-73.</p><p>Насонов Е.Л. Применение ритуксимаба при ревматоидном артрите. Науч-практич ревматол 2009;1(Прил.):3—22.</p><p>Samuels J., Ng Y.S., Coupillaud C. et al. Impaired early B cell tolerance in patients with rheumatoid arthritis. J Exp Med 2005;201:1659-67.</p><p>Takemura S., Klimiuk P.A., Braun A. et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-8.</p><p>Mauri C., Ehrenstein M.R. Cells of the synovium in rheumatoid arthritis. B cells. Arthr Res Ther 2007;9:205.</p><p>Kuhn K.A., Kulik L., Tomooka B. et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-73.</p><p>Lindenau S., Scholze S., Odendahl M. et al. Aberrant activation of B cells in patients with rheumatoid arthritis. Ann NY Acad Sci 2003;987:246-8.</p><p>Henneken M., Dö rner T., Burmester G.R., Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthr Res Ther 2005;7:R1001-R1013.</p><p>Kessel A., Snir A., Toubi E. The role of B cells in immunoregulation. In: Conrad K., Chan E.K.L., Fritzler M.J. et al. From pathogenesis to therapy of autoimmune diseases. Report on the 9th Dresden symposium on autoantibodies held in Dresden on September 2-5, 2009. Autoantigens, autoantibodies, autoimmuni-ty.Vol.6.2009. Lengerich-Berlin-Bremen-Miami-Riga-Viernheim-Wien-Zagreb: Past Science Publishers, 2009;523-30.</p><p>Wolf S.D., Dittel B.N., Hardardottir F., Janeway C.A.Jr. Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med 1996;184:2271-8.</p><p>Mizoguchi A., Bhan A.K. A case for regulatory B cells. J Immunol 2006;176:705-10.</p><p>Jamin C., Morva A., Lemoine S. et al. Regulatory B lymphocytes in humans: a potential role in autoimmunity. Arthr Rheum 2008;58:1900-6.</p><p>Amu S., Tarkowski A., Dörner T. et al. The human immunomodulatory CD25+ B cell population belongs to the memory B cell pool. Scand J Immunol 2007;66:77-86.</p><p>Taylor P.C., Quattrocchi E., Mallett St. et al. Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis 2011;70:2119-25.</p><p>Rigby W., Tony H.P., Oelke K. et al. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthr Rheum 2012;64:350-9.</p><p>Van Vollenhoven R.F., Kinnman N., Vincent E. et al. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial. Arthr Rheum 2011;63:1782-92.</p><p>Einfeld D.A., Brown J.P., Valentine M.A. et al. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988;7:711-7.</p><p>Valentine M.A., Meier K.E., Rossie S. et al. Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 1989;264:11282-7.</p><p>Stashenko P., Nadler L.M., Hardy R. et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125:1678-85.</p><p>Tedder T.F., Boyd A.W., Freedman A.S. et al. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation. J Immunol 1985;135:973-9.</p><p>Leget G.A., Czuczman M.S. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol 1998;10:548-51.</p><p>Edwards J.C., Szczepanski L., Szechinski J. et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.</p><p>Emery P., Fleischmann R., Filipowicz-Sosnowska A. et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthr Rheum 2006;54:1390-400.</p><p>Cohen S.B., Emery P., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebocontrolled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthr Rheum 2006;54:2793-806.</p><p>Leandro M.J., Cambridge G., Ehrenstein M.R., Edwards J.C.W. Reconstitution of peripheral blood B cell after depletion with rit-uximab in patients with rheumatoid arthritis. Arthr Rheum 2006;54:613-20.</p><p>Roll P., Palanichamy A., Kneitz C. et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthr Rheum 2006;54:2377-86.</p><p>Roll P., Dorner T., Tony H.-P. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthr Rheum 2008;58:1566-75.</p><p>Looney R.J. Update on the use of rituximab for intractable rheumatoid arthritis. Open Access Rheumatol Res Rev 2009;1:83-94.</p><p>De Vita S., Zaja F., Sacco S. et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthr Rheum 2002;46:2029-33.</p><p>Leandro M.J., Edwards J.C., Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.</p><p>Breedveld F., Agarwal S., Yin M. et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol 2007;47:1119-28.</p><p>Dass S., Rawstron A.C., Vital E.M. et al. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthr Rheum 2008;58:2993-9.</p><p>Vital E.M., Dass S., Rawstron A.C. et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthr Rheum 2010;62:1273-9.</p><p>Vital E.M., Rawstron A.C., Dass S. et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthr Rheum 2011;63:603-8.</p><p>Sellam J., Rouanet S., Hendel-Chavez H. et al. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthr Rheum 2011;63:3692-701.</p><p>Brezinschek H.-P., Rainer F., Brickmann K., Graninger W.B. B lymphocyte-typing for prediction of clinical response to rituximab. Arthr Res Ther 2012;14:R161.</p><p>Möller B., Aeberli D., Eggli S. et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthr Res Ther 2009;11:R62.</p><p>Teng Y.K., Levarht E.W., Toes R.E. et al. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 2009;68:1011-6.</p><p>Nakou M., Katsikas G., Sidiropoulos P. et al. Rituximab therapy reduced activated B cell in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cell correlates with clinical response. Arthr Res Therapy 2009;11:R131.</p><p>Rehnberg M., Amu S., Tarkowski A. et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthr Res Ther 2009;11:R123.</p><p>Vancsa A., Szabo Z., Szamosi S. et al. Longterm effects of rituximab on B cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow cytometry for more sensitive assessment of B cell depletion. J Rheumatol 2013;40:565-71.</p><p>Fonseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun Rev 2009;8:538-42.</p><p>Madhok R., Crilly A., Watson J., Capell H.A. Serum interleukin 6 levels in rheumatoid arthritis: correlations with clinical and laboratory indices of disease activity. Ann Rheum Dis 1993;52:232-4.</p><p>Houssiau F.A., Devogelaer J.P., van Damme J. et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthr Rheum 1988;31:784-8.</p><p>Kotake S., Sato K., Kim K.J. et al. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996;11:88-95.</p><p>Dayer J.M., Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 2010;49:15-24.</p><p>Ballara S., Taylor P.C., Reusch P. et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthr Rheum 2001;44:2055-64.</p><p>Emery P., Keystone E., Tony H.P. et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial [published erratum appears in Ann Rheum Dis 2009;68:296]. Ann Rheum Dis 2008;67:1516-23.</p><p>Roll P., Muhammad K., Schumann M. et al. In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthr Rheum 2011;63:1255-64.</p><p>Mahmood Z., Muhammad Kh., Roll P. et al. IL-6 receptor inhibition by Tocilizumab modulates double negative (CD19IgD-CD27) B Cells in RA [abstract]. Arthr Rheum 2012;64(Suppl 10):1762.</p></div><br />